Immunostimulation Versus Immunosuppression after Multiple Vaccinations: the Woes of Therapeutic Vaccine Development

被引：26

作者：

Eggermont, Alexander M. M. ^{[1
]}

机构：

[1] Erasmus Univ, Med Ctr, Daniel den Hoed Canc Ctr, NL-3075 EA Rotterdam, Netherlands

来源：

CLINICAL CANCER RESEARCH | 2009年 / 15卷 / 22期

关键词：

MELANOMA; IMMUNOTHERAPY; SURVIVAL; TRIAL;

D O I：

10.1158/1078-0432.CCR-09-2377

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Three articles in this issue of Clinical Cancer Research show how multiple vaccinations can lead to immunosuppression. Moreover, two studies in patients show that granulocyte macrophage colony-stimulating factor (GM-CSF) as an adjuvant immunostimulant to different kind of vaccines can lead to adverse outcome in terms of relapse-free and overall survival. Modulation of regulatory T-cell activity may be required to overcome this outcome and may be crucial for the successful development of therapeutic vaccines. (Clin Cancer Res 2009;15(22):6745-7)

引用

页码：6745 / 6747

页数：3

共 18 条

[1] Therapeutic vaccines in solid tumours: Can they be harmful? [J].

Eggermonf, Alexander M. M. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (12) :2087-2090

[2] EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results [J].

Eggermont, A. M. ;

Suciu, S. ;

Ruka, W. ;

Marsden, J. ;

Testori, A. ;

Corrie, P. ;

Aamdal, S. ;

Ascierto, P. A. ;

Patel, P. ;

Spatz, A. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[3] Melanoma and Immunotherapy [J].

Eggermont, Alexander M. M. ;

Schadendorf, Dirk .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (03) :547-+

[4] Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? [J].

Eggermont, AMM ;

Kirkwood, JM .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (12) :1825-1836

[5] Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Vaccination with an Allogeneic Whole-Cell Melanoma Vaccine [J].

Faries, Mark B. ;

Hsueh, Eddy C. ;

Ye, Xing ;

Hoban, Mary ;

Morton, Donald L. .

CLINICAL CANCER RESEARCH, 2009, 15 (22) :7029-7035

[6] A clinical development paradigm for cancer vaccines and related biologics [J].

Hoos, Axel ;

Parmiani, Giorgio ;

Hege, Kristen ;

Sznol, Mario ;

Loibner, Hans ;

Eggermont, Alexander ;

Urba, Walter ;

Blumenstein, Brent ;

Sacks, Natalie ;

Keilholz, Ulrich ;

Nichol, Geoffrey .

JOURNAL OF IMMUNOTHERAPY, 2007, 30 (01) :1-15

[7] Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine [J].

Hsueh, EC ;

Essner, R ;

Foshag, LJ ;

Ollila, DW ;

Gammon, G ;

O'Day, SJ ;

Boasberg, PD ;

Stern, SL ;

Ye, X ;

Morton, DL .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (23) :4549-4554

[8] High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801 [J].

Kirkwood, JM ;

Ibrahim, JG ;

Sosman, JA ;

Sondak, VK ;

Agarwala, SS ;

Ernstoff, MS ;

Rao, U .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2370-2380

[9] Partial CD4 Depletion Reduces Regulatory T Cells Induced by Multiple Vaccinations and Restores Therapeutic Efficacy [J].

LaCelle, Michael G. ;

Jensen, Shawn M. ;

Fox, Bernard A. .

CLINICAL CANCER RESEARCH, 2009, 15 (22) :6881-6890

[10] The role of vaccine therapy in the treatment of melanoma [J].

Lens, Marko .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (03) :315-323

← 1 2 →